Allergy Patient Articles & Analysis: Older
16 news found
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, ...
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut ...
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. ...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has ...
Young-Suk Kim, head of business Merck Life Science business said, “Merck will support the process of a new bispecific protein drug of GI Innovation and aims to accelerate access to cancer and allergy drugs by patients around the world. We expect that we can supply required solution to solve problems across the board, a new drug development process to ...
“With the launch of #PeanutAllergyStrong, Intrommune invites patients, parents, and everyone affected by peanut allergies to share their ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
Rejoint has teamed up with the Fraunhofer Project Centre at the University of Twente in Netherlands, and the Fruanhofer Institute for Production Technology (IPT) in Aachen, Germany, in order to develop and validate a titanium tibial tray with an embedded lattice structure for accelerating the osseointegrative process of YourKnee, Rejoint's 3D printed patient-specific implant for TKR. It will ...
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. ...
OMIT enables regular administration of allergy immunotherapy to desensitize a patient to allergies while a user brushes their teeth. ...
With the total annual avoidable expenditure on the European allergy market, not limited to rhinitis, amounting between $50 billion and $150 billion, even back in 2014, Neurent Medical's out-patient device can help customers achieve significant savings by using RF in a highly targeted manner. ...
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. ...
An Irish company developing a breakthrough therapy for a common nasal condition has raised €9.3 million. Neurent Medical, based in Oranmore, Co Galway, is developing a medical device that would allow doctors treat patients with rhinitis in their offices, rather than in a surgical setting. The funding round was led by Fountain Healthcare Partners, the Irish life sciences fund. Others ...
Allovate is licensing the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, which will focus initially on an FDA-approved treatment for peanut allergy. ...
Allovate, LLC, a specialty biopharmaceutical company, today announced that the company has signed an exclusive provider agreement with Restore Health to bring the new Allerdent OMIT System™, a personalized toothpaste system for the delivery of allergy immunotherapy, to patients nationwide. Allerdent™ is the first oral mucosal immunotherapy (OMIT) ...
A surprising number of people in Europe are suffering from allergies caused by the common ragweed, Ambrosia artemisiifolia, according to a recent study. ...